Takeda Pharmaceutical Company Limited (TAK)

Quick facts

Marketed products

• Entyvio · Gastroenterology · revenue 7300
  Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue.
• Vyvanse · Metabolic · revenue 3200
  Vyvanse works by blocking the dopamine transporter, allowing more dopamine to be available in the brain.
• Trintellix · Neuroscience · revenue 800
  Vortioxetine enhances serotonergic activity through serotonin reuptake inhibition with additional 5-HT3 antagonism and 5-HT1A agonism.
• Ninlaro · Oncology · revenue 600
  Ninlaro blocks the action of proteasomes, which are cellular complexes that break down and recycle proteins.
• Dexilant · Pain · revenue 300
  Dexlansoprazole inhibits gastric acid secretion by blocking the (H+, K+)-ATPase enzyme, known as the proton pump, in gastric parietal cells.
• Livtencity · Oncology · revenue 300
  Livtencity works by inhibiting the pUL97 kinase enzyme, which is essential for the replication of cytomegalovirus.
• AD-4833 15 mg
• Adcal-D3
• Adynovate · Other
• Nesina · Metabolic
  Nesina works by blocking an enzyme that breaks down incretin hormones, allowing more insulin to be released and less glucagon.
• Alogliptin and metformin
• Alogliptin and pioglitazone
• Omnaris · Metabolic
  Omnaris works by activating the glucocorticoid receptor to reduce inflammation in the airways.
• Agrylin · Oncology
  Agrylin works by inhibiting an enzyme that regulates platelet production, leading to a decrease in platelet count.
• Another Available A1PI · Pulmonology / Respiratory
  This drug replaces deficient alpha-1 protease inhibitor (A1PI) protein to prevent progressive lung damage in patients with alpha-1 antitrypsin deficiency.
• Anti-TNF Therapy · Immunology
  Anti-TNF therapy blocks tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.
• AO-128 · Diabetes
  AO-128 is a selective inhibitor of aldose reductase, an enzyme in the polyol pathway that converts glucose to sorbitol.
• Alunbrig · Oncology
  Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells.
• Calcichew D3 · Bone health / Nutritional supplementation
  Calcichew D3 provides supplemental calcium and vitamin D3 to maintain adequate serum calcium and phosphate levels and support bone health.
• Candesartan and Hydrochlorothiazide
• Candesartan cilexetil and hydrochlorothiazide
• Candesartan cilexetil / hydrochlorothiazide · Cardiovascular
  Candesartan cilexetil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.
• Coumarin/troxerutin · Cardiovascular / Vascular
  Coumarin/troxerutin is a bioflavonoid combination that strengthens blood vessel walls and reduces capillary fragility through antioxidant and venoprotective effects.
• Esomeprazole Capsule
• Uloric · Immunology
  Uloric works by blocking the enzyme xanthine dehydrogenase/oxidase, which is involved in the production of uric acid.
• Furazol · Neuroscience
• Glibenclamide and Metformin · Diabetes
  Glibenclamide stimulates insulin secretion from pancreatic beta cells, while metformin reduces hepatic glucose production and improves insulin sensitivity.
• Hydrochlorothiazide (HCT) · Cardiovascular
  Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure.
• HyQvia · Immunology
• Firazyr · Neuroscience
  Firazyr works by blocking the action of bradykinin, a protein that causes blood vessels to swell and leads to symptoms of HAE.
• Elaprase · Metabolic
  Elaprase works by replacing the deficient enzyme iduronate-2-sulfatase in the body.
• Kalcipos-D · Endocrinology / Bone Metabolism
  Kalcipos-D combines calcipotriol (a vitamin D analog) with calcium carbonate to regulate calcium and phosphate metabolism and promote bone mineralization.
• Leuprorelin Acetate Depot 3M · Oncology
  Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.
• LIVTENCITY
• Magnesium Esomeprazole · Gastroenterology
  Magnesium esomeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
• Metformin and insulin · Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity, while insulin directly replaces or supplements endogenous insulin to lower blood glucose.
• Banthine · Neuroscience
• Versed · Neuroscience
• Mepact · Oncology
• Exkivity · Oncology

Phase 3 pipeline

• ActHIB+ DPT-TAKEDA · Immunology / Infectious Disease
  ActHIB+ DPT-TAKEDA is a combined vaccine that provides immunization against Haemophilus influenzae type b, diphtheria, pertussis, and tetanus through active immunization.
• Alogliptin and glyburide · Diabetes
  Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while glyburide stimulates pancreatic beta cells to release insulin.
• Alogliptin and insulin · Diabetes
  Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glucose control, while insulin provides exogenous glucose-lowering activity.
• Azilsartan Medoxomil and amlodipine · Cardiovascular
  Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.
• Azilsartan medoxomil and chlorthalidone · Cardiovascular
  Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.
• Azilsartan medoxomil and hydrochlorothiazide · Cardiovascular
  Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.
• Azilsartan medoxomil and olmesartan · Cardiovascular
  This combination of two angiotensin II receptor blockers (ARBs) blocks the angiotensin II type 1 receptor to reduce blood pressure and provide cardiovascular protection.
• Azilsartan medoxomil - chlorthalidone · Cardiovascular
  Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.
• Celecoxib and aspirin · Cardiovascular / Rheumatology
  This combination uses celecoxib (a selective COX-2 inhibitor) and aspirin (a non-selective COX inhibitor) together to reduce inflammation and pain through complementary inhibition of cyclooxygenase enzymes.
• Concomitant Antibiotic Therapy · Infectious Disease
  Concomitant antibiotic therapy works by simultaneously administering multiple antibiotics to target bacteria through different mechanisms, reducing resistance and improving treatment efficacy.
• Dexlansoprazole MR · Gastroenterology
  Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells.
• Dexlansoprazole MR QD · Gastroenterology
  Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells.
• Fazirsiran Injection · Hematology / Rare Genetic Disorders
  Fazirsiran is an RNA interference (RNAi) therapeutic that silences the ALAS2 gene to reduce heme synthesis and iron accumulation in patients with iron overload disorders.
• Febuxostat IR · Rheumatology
  Febuxostat is a selective xanthine oxidase inhibitor that reduces uric acid production by blocking the enzyme responsible for converting hypoxanthine and xanthine to uric acid.
• Glimepiride and Metformin · Diabetes
  Glimepiride stimulates insulin secretion from pancreatic beta cells while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.
• IGI, 10% · Immunology
  IGI is an immunoglobulin-based therapeutic that modulates immune function through Fc receptor engagement.
• IGSC 20% infusion · Immunology
  IGSC 20% is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.
• Lansoprazole and naproxen and aspirin · Gastroenterology / Rheumatology
  This combination product reduces gastric acid secretion via lansoprazole while providing anti-inflammatory and analgesic effects through naproxen and aspirin, with the proton pump inhibitor protecting against NSAID-induced gastrointestinal injury.
• Lansoprazole microgranules suspension · Gastroenterology
  Lansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
• Lapaquistat acetate and atorvastatin · Cardiovascular
  Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while atorvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis.
• Lapaquistat acetate and ezetimibe · Cardiovascular
  Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while ezetimibe blocks NPC1L1 to further decrease cholesterol uptake, together lowering LDL cholesterol.
• Lapaquistat acetate and rosuvastatin · Cardiovascular
  Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis.
• Lapaquistat acetate and simvastatin · Cardiovascular
  Lapaquistat acetate inhibits ACAT (acyl-CoA:cholesterol acyltransferase) to reduce cholesterol absorption, while simvastatin inhibits HMG-CoA reductase to decrease cholesterol synthesis, providing dual lipid-lowering effects.
• Leuprorelin acetate · Oncology
  Leuprorelin acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.
• Lipid-lowering therapy · Cardiovascular
  Lipid-lowering therapy reduces blood cholesterol and triglyceride levels through various pharmacological mechanisms to prevent cardiovascular disease.
• Magnesium Pantoprazole · Gastroenterology
  Magnesium pantoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
• Placebo to alogliptin · Diabetes
  Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes.
• Placebo to match deucravacitinib · Immunology
  Deucravacitinib is a small molecule that acts as a selective tyrosine kinase 2 (TYK2) inhibitor.
• Placebo to match zasocitinib
  This drug is a placebo used to match the effects of zasocitinib.
• Rapid-acting insulin secretagogue
• SOC 4F-PCC · Cardiovascular
  SOC 4F-PCC is a Factor IIa protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin signaling to reduce thrombotic events.
• Surgicel® Original · Surgery/Hemostasis
  Surgicel® Original is an oxidized cellulose hemostatic agent that promotes blood clotting and controls bleeding at surgical sites.
• SYR-322-MET · Diabetes
  SYR-322-MET is a glucagon-like peptide-1 (GLP-1) receptor agonist.
• SYR-472 · Oncology
  SYR-472 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.
• TAK-003 · Immunology / Infectious Disease
  TAK-003 is a live attenuated tetravalent dengue vaccine that stimulates immune responses against all four dengue virus serotypes.
• TAK-019 · Oncology
  TAK-019 is a therapeutic vaccine designed to stimulate immune responses against cancer cells expressing specific tumor-associated antigens.
• TAK-279 · Diabetes
  TAK-279 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• TAK-330
  TAK-330 is an investigational drug with a mechanism that is not fully disclosed publicly.
• TAK-385 · Diabetes
  TAK-385 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• TAK-438 · Diabetes
  TAK-438 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

Phase 2 pipeline

• Alogliptin and glimepiride · Diabetes
  Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and glimepiride is a sulfonylurea that stimulates insulin release.
• Alogliptin and voglibose · Diabetes
  Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while voglibose is an alpha-glucosidase inhibitor.
• Amoxicillin hydrate · Infectious diseases
  Amoxicillin hydrate is a beta-lactam antibiotic that inhibits cell wall synthesis in bacteria.
• Any FDA Approved ALK Inhibitors · Oncology
  ALK tyrosine kinase inhibitor
• Chemotherapy Agents · Oncology
  Topoisomerase inhibitor
• Freeze-dried Human Protein C Concentrate · Cardiovascular
  Freeze-dried Human Protein C Concentrate works by replacing a clotting factor in the blood to prevent excessive clotting.
• Influenza HA vaccine
• Lapaquistat acetate and fenofibrate
• Levothyroxine sodium new formulation · Endocrinology
  Levothyroxine sodium acts on the thyroid hormone receptor.
• MCC-135
• NDI-034858
• NE-58095 DR
• NE-58095 IR
• NesinaAct® Tablet
• Norovirus Bivalent VLP Vaccine
• NoV Vaccine
• Omega-3 fatty acid ethyl esters · Cardiovascular
  Activates peroxisome proliferator-activated receptor alpha (PPAR-alpha)
• Other Biological Agent
• Pioglitazone and atorvastatin
• Pioglitazone and ramipril
• Pioglitazone and sulphonylurea
• Ramelteon and doxepin
• Ramelteon and gabapentin
• Recombinant ADAMTS13
• TAK-007
• TAK-062
• TAK-079
• TAK-101
• TAK-113
• TAK-226
• TAK-272
• TAK-341
• TAK-360
• TAK-411
• TAK-442
• TAK-577
• TAK-583
• TAK-672
• TAK-715 and methotrexate
• TAK-783 and methotrexate

Phase 1 pipeline

• [^11C]T-773
• [14C]-TAK-385 Oral Solution
• [14C]TAK-935 IV Infusion
• [14C]TAK-935 Oral Solution
• [14C]TAK-994 Intravenous Infusion
• [14C]TAK-994 Oral Suspension
• Clopidogrel and Dexlansoprazole
• Clopidogrel and Esomeprazole
• Clopidogrel and Lansoprazole
• Clopidogrel and Omeprazole
• Dexlansoprazole Delayed Release Capsules
• GDX012
• Intramuscular injection of TAK-850
• Maalox Advance Regular Strength liquid
• mannitol and sucrose
• Maribavir Commercial Tablet Formulation
• Noncarbonated Water
• Norovirus Bivalent Vaccine
• Norwalk VLP vaccine
• PIZV
• Second generation antipsychotic
• Soticlestat 300 mg
• Subcutaneous injection of TAK-850
• SYR-322-4833 BL
• SYR-322MET
• TAK-004
• TAK-020 Captisol Oral Solution
• TAK-020 CCT
• TAK-020 IRT
• TAK-020 SDT
• TAK-020 Solid Formulation
• TAK-063
• TAK-105-a
• TAK-123
• TAK-165
• TAK-188
• TAK-227
• TAK-233

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Takeda Pharmaceutical Company Limited portfolio CI brief
• Takeda Pharmaceutical Company Limited pipeline updates RSS